👤 Shude Xu

🔍 Search 📋 Browse 🏷️ Tags ❤️ Favourites ➕ Add 🧬 Extraction
1613
Articles
1035
Name variants
Also published as: Ting-Xin Xu, Shuang Xu, Renyuan Xu, Cheng Xu, Xiao Xu, Jia-Chen Xu, Shengjie Xu, Yanyong Xu, Nong Xu, D-J Xu, Hongfa Xu, Shiyi Xu, Yunjian Xu, Maochang Xu, Lingyan Xu, Guoheng Xu, Zaibin Xu, Yuexuan Xu, Jinhe Xu, Yitong Xu, Yaping Xu, Miao Xu, Hongming Xu, Jiang Xu, Feng-Qin Xu, Zaihua Xu, Yaru Xu, Qiuyu Xu, Yuanzhong Xu, Mingcong Xu, Mai Xu, Biao Xu, Jingjun Xu, Shuwan Xu, Ya-Ru Xu, Zhilong Xu, Jun-Chao Xu, Shutao Xu, TianBo Xu, Jinyu Xu, Jie-Hua Xu, Peng Xu, Guo-Xing Xu, Yushan Xu, Yongsong Xu, Xin-Rong Xu, Xiang-Min Xu, Bilin Xu, Xiaolong Xu, Jinchao Xu, Han Xu, Xuting Xu, Yu Xu, Yingqianxi Xu, Yanyang Xu, Aili Xu, Weizhi Xu, Peidi Xu, Tongyang Xu, Tieshan Xu, Jianping Xu, Wen-Juan Xu, Bing Xu, Chengyun Xu, Xiaofeng Xu, Zhengang Xu, Guang-Hong Xu, Fangui Xu, Shan-Shan Xu, Song-Song Xu, Hailiang Xu, Quanzhong Xu, Mengqi Xu, Gezhi Xu, Dawei Xu, Linyan Xu, Yidan Xu, Meishu Xu, Tonghong Xu, Panpan Xu, Keli Xu, Xiufeng Xu, Hongwen Xu, Hanyuan Xu, Liang Xu, Zaoyi Xu, Fengqin Xu, Run-Xiang Xu, Xiaoyan Xu, Ruxiang Xu, Huiming Xu, Daqian Xu, Qin-Zhi Xu, Jiancheng Xu, Boming Xu, Zihao Xu, Jinghong Xu, Aimin Xu, Renfang Xu, Ran Xu, Di-Mei Xu, Xiang-liang Xu, Yana Xu, Richard H Xu, Yanchang Xu, Danyi Xu, Chengqi Xu, Lingli Xu, Xiaocheng Xu, Xiaoshuang Xu, H X Xu, Min Xu, Ya'nan Xu, Zhi Ping Xu, Zihe Xu, Hongle Xu, Xuan Xu, Jielin Xu, Yuping Xu, Limin Xu, Yinli Xu, Renshi Xu, Da Xu, C C Xu, Yongqing Xu, Heping Xu, Yiquan Xu, Jingjing Xu, Weilan Xu, Yangxian Xu, Yifan Xu, Congjian Xu, Binqiang Xu, Wentao Xu, Yuerong Xu, Jiaqi Xu, Shang-Fu Xu, Jiachi Xu, Zhi-Qing David Xu, Yuejuan Xu, Chao Xu, Yi-Xian Xu, Longfei Xu, Ziwei Xu, Mengyue Xu, Jingying Xu, Wenhui Xu, Zi-Xiang Xu, Caixia Xu, Chenjie Xu, Xiaoting Xu, Jiacheng Xu, Chunhui Xu, Chengxun Xu, Hengyi Xu, Songsong Xu, Lingyao Xu, Qingqiu Xu, Gangchun Xu, Yanjun Xu, Wenxuan Xu, Qiong Xu, Zifan Xu, Jiayunzhu Xu, Yifeng Xu, DongZhu Xu, Lingna Xu, Qianzhu Xu, Bocheng Xu, Qingjia Xu, Yanni Xu, Li-Yan Xu, Benhong Xu, Fang Xu, Xingsheng Xu, Geyang Xu, Anqi Xu, Zeao Xu, Mengsi Xu, Jun Xu, Qiuhong Xu, Ning'an Xu, Lian-Wei Xu, H F Xu, Hua Xu, Danping Xu, Xiaofang Xu, Shanshan Xu, Sheng-Qian Xu, Bingxin Xu, Ke Xu, Shiqing Xu, Cunshuan Xu, Guangwei Xu, Beibei Xu, Changwu Xu, Zhuangzhuang Xu, Chong-Feng Xu, Yunyi Xu, Yunxuan Xu, Zeya Xu, Jinshu Xu, Laizhi Xu, Xinyu Xu, Meiyu Xu, Bi-Yun Xu, Mingliang Xu, Weixia Xu, Bingfang Xu, Suling Xu, W W Xu, Lidan Xu, Chengkai Xu, Feng Xu, Yunhe Xu, Zesheng Xu, Li Xu, Song Xu, Yungen Xu, Yaobo Xu, Qinli Xu, Yi-Liang Xu, Dong Xu, Tan Xu, Ruiling Xu, Wanqi Xu, Ziyang Xu, Xiaohong Ruby Xu, Guangyu Xu, Xiao-Shan Xu, Wenxin Xu, Yongsheng Xu, Jingya Xu, Zhong-Hua Xu, Jiajie Xu, Dan Xu, Youjia Xu, Longsheng Xu, Mengjie Xu, Guo-Tong Xu, Ting Xu, Chunwei Xu, Tianmin Xu, Xianghong Xu, Nenggui Xu, Hongxia Xu, Meixi Xu, Rongying Xu, Guoliang Xu, Lisi Xu, Leisheng Xu, Yurui Xu, Xianli Xu, Honglin Xu, Yunfang Xu, Guo Xu, Shengyu Xu, Kelin Xu, Xiaoqin Xu, Zheng Xu, Junchang Xu, Jiaying Xu, Beisi Xu, Chunyu Xu, Zhen-Guo Xu, Haonan Xu, Tianyi Xu, Haiman Xu, Lili Xu, Yi Xu, Dongju Xu, Qihang Xu, Zihua Xu, Zhongwei Xu, Qikui Xu, Li-Jun Xu, Zhijie Xu, Hanchen Xu, Qi-Qi Xu, Yaqi Xu, Daohua Xu, Shaonian Xu, Xihui Xu, D Xu, Ziqi Xu, Tian-Ying Xu, Xiangbin Xu, Chen-Run Xu, Bin Xu, Jianjuan Xu, Zhanyu Xu, Wenjie Xu, Lingjuan Xu, Shuwen Xu, Yu-Ming Xu, Cian Xu, Qiulin Xu, Zeyu Xu, Jia Xu, Zengliang Xu, Yujie Xu, Yuting Xu, Jing-Yi Xu, Jiajia Xu, Xiqi Xu, Leiyu Xu, Shi-Na Xu, Ruonan Xu, Wenhuan Xu, Bai-Hui Xu, Jishu Xu, Xiangyu Xu, Lu-Lu Xu, Shiyun Xu, Huaxiang Xu, Lei Xu, Yuli Xu, Chan Xu, Tengfei Xu, Yong Xu, Xuejun Xu, Hang Xu, Jinjie Xu, Junjie Xu, Haoda Xu, Rui-Ming Xu, Yunxi Xu, Jinghua Xu, Ye Xu, Jiyi Xu, Mei-Jun Xu, Jianyong Xu, Yingzheng Xu, Kaiyue Xu, Yeqiu Xu, Songli Xu, Chenqi Xu, Cheng-Jian Xu, Qiaoshi Xu, Rongrong Xu, YanFeng Xu, Jin Xu, Huimian Xu, Zaikun Xu, Aixiao Xu, Yanfei Xu, Chunlin Xu, Huiqiong Xu, Dapeng Xu, Fengxia Xu, Yongmei Xu, Yubin Xu, Xiaojing Xu, Xiaoli Xu, Pu Xu, Wenming Xu, Wenjing Xu, Wenjuan Xu, Haijin Xu, Yawei Xu, Chuanrui Xu, Wenping Xu, Tongtong Xu, Yinfeng Xu, Zhigang Xu, Zi-Hua Xu, Jiean Xu, Ming Xu, Keshu Xu, Weili Xu, Guofeng Xu, Ai-Guo Xu, Xingyu Xu, Shujing Xu, Weiqun Xu, Wen-Hao Xu, Hong-wei Xu, Jianfeng Xu, Y Xu, Steven Jing-Liang Xu, Fangfang Xu, Xiao-Dan Xu, Keyun Xu, Yetao Xu, Qianhui Xu, Chaoqun Xu, Yuzhi Xu, Fenghuang Xu, Tengxiao Xu, Zelin Xu, Xueni Xu, Jing-Ying Xu, Yichi Xu, Ruifeng Xu, Kewei Xu, Jiapeng Xu, Fang-Fang Xu, Sifan Xu, Pengli Xu, Jiaqin Xu, Xiaotao Xu, Chunming Xu, X Xu, Gang Xu, Xinyin Xu, Wei Xu, Yuzhen Xu, Wancheng Xu, Qiming Xu, Hailey Xu, Yuanyuan Xu, Yimeng Xu, Xiaoming Xu, Shihao Xu, Zhipeng Xu, Minxuan Xu, Haowen Xu, Dilin Xu, Rui Xu, Jingzhou Xu, Qiongying Xu, Zhengshui Xu, Jinyi Xu, Q P Xu, Yongjian Xu, Qiushi Xu, Junfei Xu, Mengjun Xu, Hui Ming Xu, Yanzhe Xu, Xiaolei Xu, Qin Xu, Zichuan Xu, Xinyun Xu, Tianyu Xu, Xiaoge Xu, Yigang Xu, Hongyan Xu, Lanjin Xu, Guowang Xu, Jingjie Xu, Yangyang Xu, Yi-Huan Xu, Guanhua Xu, Hongrong Xu, Fen Xu, Jian Xu, Pin-Xian Xu, Tiantian Xu, Zhonghui Xu, Changfu Xu, Dong-Hui Xu, Yi-Ni Xu, Jialu Xu, Yuzhong Xu, Hongli Xu, Mingyuan Xu, Minghao Xu, C F Xu, Qinghua Xu, Yiting Xu, Qian Xu, Jiahong Xu, Haixiang Xu, Xizheng Xu, Kun Xu, Yunfei Xu, Xiaoyang Xu, Xiaojun Xu, Xinyuan Xu, Chen Xu, Guogang Xu, Guiyun Xu, Jinguo Xu, Lingyi Xu, Chunjie Xu, Wenbin Xu, Cheng-Bin Xu, Manman Xu, Dongke Xu, Jia-Mei Xu, Bing-E Xu, Lijiao Xu, You-Song Xu, Yu-Xin Xu, Mengmeng Xu, Jianwei Xu, Kuanfeng Xu, Chun Xu, Shiliyang Xu, Waner Xu, Zhiyao Xu, Gu-Feng Xu, J T Xu, Wenyuan Xu, Haifeng Xu, Ling Xu, Chaohua Xu, Lisha Xu, Huaisha Xu, Xiayun Xu, Qian-Fei Xu, Jinying Xu, Tengyun Xu, Chaoguang Xu, Fuyi Xu, Shihui Xu, Yingna Xu, Aishi Xu, Yanyan Xu, Bilian Xu, Qiuhui Xu, Jinsheng Xu, Qinwen Xu, Tianfeng Xu, Lihui Xu, Liyi Xu, Guanyi Xu, Wenyan Xu, Ru-xiang Xu, Zongzhen Xu, Nan Xu, Jinxian Xu, Rui-Xia Xu, Zhiting Xu, Jiaming Xu, Shan-Rong Xu, Yi-Tong Xu, Xiaojuan Xu, Guifa Xu, Xia-Jing Xu, Libin Xu, Dequan Xu, Guoxu Xu, Hong Xu, Cai Xu, Lubin Xu, Mengying Xu, Tian-Le Xu, J Xu, Weidong Xu, Chengbi Xu, Yibin Xu, Cong-jian Xu, Qianlan Xu, Tingting Xu, Caiqiu Xu, Hong-Yan Xu, Hanqian Xu, Xiao Le Xu, Bei Xu, Guanlan Xu, Jianxin Xu, Ming-Zhu Xu, Long Xu, Xiaopeng Xu, Yinjie Xu, Shufen Xu, Zhihua Xu, Ming-Jiang Xu, Di Xu, Qingwen Xu, Jiake Xu, Tingxuan Xu, Ping Xu, Peng-Ju Xu, Shang-Rong Xu, Li-Zhi Xu, Baoping Xu, Huan Xu, Wenwu Xu, Zhenyu Xu, Chong Xu, Sihua Xu, Anlong Xu, Lu Xu, Chen-Yang Xu, Xiaoyu Xu, Zhe Xu, Qiuyue Xu, Guangquan Xu, Peiyu Xu, Huihui Xu, Ding Xu, Yuchen Xu, Jianguo Xu, Xuegong Xu, Lingyang Xu, Jia-Yue Xu, Liping Xu, Yuling Xu, Yiyi Xu, Jianqiu Xu, Lichi Xu, Xiaojiang Xu, Xiao-Hui Xu, Mao Xu, Yuyang Xu, Zhaofa Xu, Qingchan Xu, Yanli Xu, Julie Xu, Minglan Xu, G Xu, Miaomiao Xu, Yao Xu, Yali Xu, Yanqi Xu, Tian Xu, Xiaojin Xu, Xiaowen Xu, Qing-Yang Xu, Lingxiang Xu, Jianguang Xu, Zhanchi Xu, Shiwen Xu, Haikun Xu, Hongbei Xu, Yixin Xu, Zhan Xu, Xingshun Xu, Wenzhuo Xu, Fangmin Xu, Fu Xu, Haimin Xu, Shengtao Xu, Jiahui Xu, Zhiwei Xu, Peiwei Xu, Daichao Xu, Wen-Hui Xu, Xingyan Xu, H Eric Xu, Zhi-Feng Xu, Mingming Xu, Hongtao Xu, Daiqi Xu, Keman Xu, Yinying Xu, Yuexin Xu, Yuanwei Xu, L Xu, Jinfeng Xu, Xuanqi Xu, Chunyan Xu, Hanting Xu, Chaoyu Xu, Shendong Xu, Tiancheng Xu, Chentong Xu, Guangsen Xu, Yaozeng Xu, Banglao Xu, Tao Xu, Danyan Xu, Ren-He Xu, Haiyan Xu, Jian-Guang Xu, Yu-Fen Xu, Youzhi Xu, Hui Xu, Enwei Xu, F F Xu, Ningda Xu, Zejun Xu, Li-Wei Xu, N Y Xu, Xiaoya Xu, Ren Xu, Ze-Jun Xu, Yanan Xu, Jiapei Xu, Peigang Xu, Tianxiang Xu, Haiqi Xu, Qing-Wen Xu, Junnv Xu, Tian-Rui Xu, Wanfu Xu, Wang-Hong Xu, Maotian Xu, Suoyu Xu, Mingli Xu, Qingqing Xu, Liwen Xu, Zhenming Xu, Jingyi Xu, Yihua Xu, Dong-Juan Xu, Mu Xu, Meifeng Xu, Li-Ling Xu, Dongmei Xu, Jianliang Xu, Pengfei Xu, Xinjie Xu, Changlin Xu, Shuai Xu, Fang-Yuan Xu, Yingli Xu, Ying Xu, Guo-Liang Xu, Zhiqiang Xu, Xirui Xu, Haiying Xu, Wen Xu, Xiaoyin Xu, Wenwen Xu, Mengping Xu, Jing-Yu Xu, Chunlan Xu, Danfeng Xu, Yuan Xu, Zekuan Xu, Wenchun Xu, Nuo Xu, Shuxiang Xu, Min Jie Xu, Penghui Xu, Zixuan Xu, Bingqi Xu, Hongen Xu, Zongli Xu, Tianli Xu, Bo Xu, Zhaojun Xu, Qingyuan Xu, Shuhua Xu, Min-Xuan Xu, Xu Xu, M Xu, Runhao Xu, Xiongfei Xu, Zhaoyao Xu, Yingju Xu, Yayun Xu, Kaixiang Xu, Guang-Qing Xu, Lingling Xu, Jiyu Xu, Anton Xu, Jason Xu, Donghang Xu, Xiaowu Xu, Fengzhe Xu, Xia Xu, Xiangshan Xu, Wan-Ting Xu, Fengyan Xu, Qingheng Xu, Changlu Xu, Huaiyuan Xu, Jinsong Xu, Dongchen Xu, Rang Xu, Peng-Yuan Xu, Jinyuan Xu, Weihong Xu, Wanxue Xu, Xinyi Xu, Jie Xu, Junfeng Xu, Danning Xu, Haiming Xu, Sutong Xu, Shan Xu, Meng Xu, Yueyue Xu, Jixuan Xu, Hongjian Xu, Zhidong Xu, Jinjin Xu, Xiaobo Xu, Hongmei Xu, Shu-Xian Xu, Chuang Xu, Shuaili Xu, Zhixian Xu, Yun Xu, Yue Xu, George X Xu, Man Xu, Jiaai Xu, Zeqing Xu, Baijie Xu, Zheng-Fan Xu, Bojie Xu, Mengru Xu, H Y Xu, Yinhe Xu, Linna Xu, Liqun Xu, Zhi-Zhen Xu, Xiaohui Xu, Xingmeng Xu, Yinxia Xu, Pan Xu, Pengjie Xu, Kexin Xu, Kai Xu, Cun Xu, Xiaolin Xu, Yuxiang Xu, Tong Xu, Jingyu Xu, Li-Li Xu, Yancheng Xu, Chunxiao Xu, Yan Xu, Huajun Xu, Hongjiang Xu, Shuiyang Xu, Kaihao Xu, Suo-Wen Xu, Heng Xu, Zebang Xu, Hongbo Xu, Chenhao Xu, Fanghua Xu, Yaowen Xu, Jing Xu, Qianqian Xu, Andrew Z Xu, Flora Mengyang Xu, Yuanzhi Xu, Leilei Xu, Leyuan Xu, M-Y Xu, Hongzhi Xu, Zongren Xu, Xinyue Xu, Qingxia Xu, Xiao-Hua Xu, Cineng Xu, Nannan Xu, Guoshuai Xu, Mingzhu Xu, X S Xu, Guang Xu, Song-Hui Xu, Zhiyang Xu, Wang-Dong Xu, De-Xiang Xu, Yi Ran Xu, Shengen Xu, Jianzhong Xu, F Xu, Dexiang Xu, Rui-Hua Xu, Tongxin Xu, Wanting Xu, Bingqian Xu, Jiaqian Xu, Yang Xu, Yu-Ping Xu, Zhanqiong Xu, Haixia Xu, Hao Xu, HuiTing Xu, Hanfei Xu, Shu-Zhen Xu, Zhong Xu, Xun Xu, Xiaolu Xu, S Xu, Ning Xu, Guangyan Xu, Chengye Xu, Xizhan Xu, Ya-Peng Xu, Jianming Xu, Wenhao Xu, Minghong Xu, Mingqian Xu, Yaqin Xu, Chang-Qing Xu, Weiyong Xu, Huixuan Xu, Jialin Xu, Fei Xu, Z Xu, Pao Xu, Youping Xu, Keke Xu, Shunjiang Xu, Feilai Xu, Jia-Li Xu, Yucheng Xu, Qi Xu, Jinhua Xu, Chunli Xu, Zhiliang Xu, Jinxin Xu, Lianjun Xu, Bingqing Xu, Weihai Xu, Lifen Xu, Wenqi Xu, Zheng-Hong Xu, Lin Xu, Zuojun Xu, Yanquan Xu, Yanwu Xu, Mingjie Xu, Hui-Lian Xu, Dongjun Xu, Cong Xu, Maodou Xu, Rong Xu, Haoyang Xu, Shanhai Xu, Yinglin Xu, Haoyu Xu, Wenqing Xu, Jiali Xu, Xiaoke Xu, Changliu Xu, Feng-Xia Xu, Carrie Xu, Yuheng Xu, Shimeng Xu, Wanwan Xu, Weiming Xu, Gui-Ping Xu, Zhenzhou Xu, Yangbin Xu, Aohong Xu, Wenlong Xu, Jia-Xin Xu, Luyi Xu, Manyi Xu, De Xu, Xinxuan Xu, Changde Xu, Gaosi Xu, Baofeng Xu, Chang Xu, Wanhai Xu, Qing Xu, Zuyuan Xu, Pingwen Xu, Feng-Yuan Xu, Aoling Xu, Erping Xu, Shaoqi Xu, Zhicheng Xu, Lun-Shan Xu, Shiyao Sherrie Xu, Jianing Xu, Boqing Xu, Janfeng Xu, Yin Xu, Weijie Xu, Yu-Peng Xu, Ya-Nan Xu, Gaoyuan Xu, Iris M J Xu, Zhi Xu, Xiaomeng Xu, Mengyi Xu, Meifang Xu, Houxi Xu, Yuanfeng Xu, Shuqia Xu, Da-Peng Xu, Hong-tao Xu, Yaling Xu, Mei Xu, Xiaojiao Xu, Zhiru Xu, Weide Xu, Dandan Xu, W Xu, Shun Xu, Jianhua Xu, Tongda Xu, Cynthia M Xu, Yechun Xu, Lijun Xu, Xiao-Lin Xu, Ziye Xu, Xiaohan Xu, Guozheng Xu, Rongbin Xu, Nathan Xu, Wangdong Xu, Kailian Xu, Yongfeng Xu, Zhunan Xu, Ruohong Xu, Jiawei Xu, Yuhan Xu, Shanqi Xu, Shoujia Xu, T Xu, Weifeng Xu, Qiuyun Xu, Hu Xu, Yanming Xu, Hongwei Xu, Ziyu Xu, Kaishou Xu, Jian Hua Xu, Xin Xu, Liu Xu, Zetan Xu, Leiting Xu, Yong-Nan Xu, Houguo Xu, Zhizhen Xu, Ya-lin Xu, Xiang Xu, Suowen Xu, Xuejin Xu, Yiming Xu, Genxing Xu, Yun-Teng Xu, Yanling Xu, Yuanhong Xu, Lijuan Xu, Xingzhi Xu, Guanghao Xu, Qiu-Han Xu, Siqun Xu, Wen-Xiong Xu, Qianghua Xu, Shuangbing Xu, Wenjun Xu, Jiangang Xu, Yangliu Xu, Jinjian Xu, W M Xu, Shanqiang Xu, Zefeng Xu
articles
Xiangyu Hu, Chunmiao Hu, Liting Liao +7 more · 2024 · Scandinavian journal of immunology · Blackwell Publishing · added 2026-04-24
Isoliquiritigenin (ISL) is a chalcone-type flavonoid derived from the root of licorice with antioxidant, anti-inflammatory, anti-tumour and neuroprotective properties. ISL has been proven to downregul Show more
Isoliquiritigenin (ISL) is a chalcone-type flavonoid derived from the root of licorice with antioxidant, anti-inflammatory, anti-tumour and neuroprotective properties. ISL has been proven to downregulate the productions of IL-1β, TNF-α and IL-6 by macrophages. However, detailed molecular mechanisms of this modulation remain elusive. Here, ISL suppressed Syk phosphorylation and CD80, CD86, IL-1β, TNF-α and IL-6 expressions in lipopolysaccharide-stimulated macrophages ex vivo. ApoC3-transgenic (ApoC3 Show less
no PDF DOI: 10.1111/sji.13371
APOC3
Mei-Jie Chen, Yi-Tong Xu, Lu Sun +6 more · 2024 · Acta pharmacologica Sinica · Nature · added 2026-04-24
Within the context of residual cardiovascular risk in post-statin era, emerging evidence from epidemiologic and human genetic studies have demonstrated that triglyceride (TG)-rich lipoproteins and the Show more
Within the context of residual cardiovascular risk in post-statin era, emerging evidence from epidemiologic and human genetic studies have demonstrated that triglyceride (TG)-rich lipoproteins and their remnants are causally related to cardiovascular risk. While, carriers of loss-of-function mutations of ApoC3 have low TG levels and are protected from cardiovascular disease (CVD). Of translational significance, siRNAs/antisense oligonucleotide (ASO) targeting ApoC3 is beneficial for patients with atherosclerotic CVD. Therefore, animal models of atherosclerosis with both hypercholesterolemia and hypertriglyceridemia are important for the discovery of novel therapeutic strategies targeting TG-lowering on top of traditional cholesterol-lowering. In this study, we constructed a novel mouse model of familial combined hyperlipidemia through inserting a human ApoC3 transgene (hApoC3-Tg) into C57BL/6 J mice and injecting a gain-of-function variant of adeno-associated virus-proprotein convertase subtilisin/kexin type 9 (AAV-PCSK9)-D377Y concurrently with high cholesterol diet (HCD) feeding for 16 weeks. In the last 10 weeks, hApoC3-Tg mice were orally treated with a combination of atorvastatin (10 mg·kg Show less
no PDF DOI: 10.1038/s41401-024-01241-8
APOC3
Shengxi Shen, Ping Wang, Pei Wu +4 more · 2024 · Molecular therapy : the journal of the American Society of Gene Therapy · Elsevier · added 2026-04-24
Wnt/β-catenin signaling is an attractive target for regenerative medicine. A powerful driver of stem cell activity and hence tissue regeneration, Wnt signaling can promote fibroblast proliferation and Show more
Wnt/β-catenin signaling is an attractive target for regenerative medicine. A powerful driver of stem cell activity and hence tissue regeneration, Wnt signaling can promote fibroblast proliferation and activation, leading to fibrosis, while prolonged Wnt signaling is potentially carcinogenic. Thus, to harness its therapeutic potential, the activation of Wnt signaling must be transient, reversible, and tissue specific. In the lung, Wnt signaling is essential for alveolar stem cell activity and alveolar regeneration, which is impaired in lung fibrosis. Activation of Wnt/β-catenin signaling in lung epithelium may have anti-fibrotic effects. Here, we used intratracheal adeno-associated virus 6 injection to selectively deliver CasRx into the lung epithelium, where it reversibly activates Wnt signaling by simultaneously degrading mRNAs encoding Axin1 and Axin2, negative regulators of Wnt/β-catenin signaling. Interestingly, CasRx-mediated Wnt activation specifically in lung epithelium not only promotes alveolar type II cell proliferation and alveolar regeneration but also inhibits lung fibrosis resulted from bleomycin-induced injury, relevant in both preventive and therapeutic settings. Our study offers an attractive strategy for treating pulmonary fibrosis, with general implications for regenerative medicine. Show less
📄 PDF DOI: 10.1016/j.ymthe.2024.09.008
AXIN1
Fangchen Gong, Wenbin Liu, Lei Pei +10 more · 2024 · Frontiers in endocrinology · Frontiers · added 2026-04-24
Sepsis, a life-threatening condition, involves complex interactions among metabolic alterations, inflammatory mediators, and host responses. This study utilized a bidirectional Mendelian randomization Show more
Sepsis, a life-threatening condition, involves complex interactions among metabolic alterations, inflammatory mediators, and host responses. This study utilized a bidirectional Mendelian randomization approach to investigate the causal relationships between 1400 metabolites and sepsis, and the mediating role of inflammatory factors. We identified 36 metabolites significantly associated with sepsis (p < 0.05), with AXIN1, FGF-19, FGF-23, IL-4, and OSM showing an inverse association, suggesting a protective role, while IL-2 exhibited a positive correlation, indicating a potential risk factor. Among these metabolites, Piperine and 9-Hydroxystearate demonstrated particularly interesting protective effects against sepsis. Piperine's protective effect was mediated through its interaction with AXIN1, contributing to a 16.296% reduction in sepsis risk. This suggests a potential pathway where Piperine influences sepsis outcomes by modulating AXIN1 levels. 9-Hydroxystearate also exhibited a protective role against sepsis, mediated through its positive association with FGF-19 and negative association with IL-2, contributing 9.436% and 12.565%, respectively, to its protective effect. Experimental validation confirmed significantly elevated IL-2 levels and reduced FGF-19, AXIN1, piperine, and 9-hydroxyoctadecanoic acid levels in sepsis patients compared to healthy controls. Piperine levels positively correlated with AXIN1, while 9-hydroxyoctadecanoic acid levels negatively correlated with IL-2 and positively correlated with FGF-19, supporting the Mendelian randomization findings. Our findings provide insights into the molecular mechanisms of sepsis, highlighting the unique roles and contributions of specific metabolites and their interactions with inflammatory mediators. This study enhances our understanding of sepsis pathophysiology and opens avenues for targeted therapeutic interventions and biomarker development for sepsis management. However, further research is essential to validate these pathways across diverse populations and fully explore the roles of these metabolites in sepsis. Show less
📄 PDF DOI: 10.3389/fendo.2024.1377755
AXIN1
Dongdong Zhou, Dandan Chen, Jingwan Wu +3 more · 2024 · Marine drugs · MDPI · added 2026-04-24
Overwhelming evidence points to an aberrant Wnt/β-catenin signaling as a critical factor in hepatocellular carcinoma (HCC) and cervical cancer (CC) pathogenesis. Dicerandrol C (DD-9), a dimeric tetrah Show more
Overwhelming evidence points to an aberrant Wnt/β-catenin signaling as a critical factor in hepatocellular carcinoma (HCC) and cervical cancer (CC) pathogenesis. Dicerandrol C (DD-9), a dimeric tetrahydroxanthenone isolated from the endophytic fungus Show less
📄 PDF DOI: 10.3390/md22060278
AXIN1
Bin Yang, Zebang Xu, Yilang Qin +3 more · 2024 · BMC veterinary research · BioMed Central · added 2026-04-24
The current understanding to the mechanism of rumen development is limited. We hypothesized that the Hippo signaling pathway controlled the proliferation of rumen epithelium (RE) during postnatal deve Show more
The current understanding to the mechanism of rumen development is limited. We hypothesized that the Hippo signaling pathway controlled the proliferation of rumen epithelium (RE) during postnatal development. In the present study, we firstly tested the changes of the Hippo signaling pathway in the RE during an early growing period from d5 to d25, and then we expanded the time range to the whole preweaning period (d10-38) and one week post weaning (d45). An in vitro experiment was also carried out to verify the function of Hippo signaling pathway during RE cell proliferation. In the RE of lambs from d5 to d25, the expression of baculoviral IAP repeat containing (BIRC3/5) was increased, while the expressions of large tumor suppressor kinase 2 (LATS2), TEA domain transcription factor 3 (TEAD3), axin 1 (AXIN1), and MYC proto-oncogene (MYC) were decreased with rumen growth. From d10 to d38, the RE expressions of BIRC3/5 were increased, while the expressions of LATS2 and MYC were decreased, which were similar with the changes in RE from d5 to d25. From d38 to d45, different changes were observed, with the expressions of LATS1/2, MOB kinase activator 1B (MOB1B), and TEAD1 increased, while the expressions of MST1 and BIRC5 decreased. Correlation analysis showed that during the preweaning period, the RE expressions of BIRC3/5 were positively correlated with rumen development variables, while LAST2 was negatively correlated with rumen development variables. The in vitro experiment validated the changes of LATS2 and BIRC3/5 in the proliferating RE cells, which supported their roles in RE proliferation during preweaning period. Our results suggest that the LATS2-YAP1-BIRC3/5 axis participates in the RE cell proliferation and promotes rumen growth during the preweaning period. Show less
📄 PDF DOI: 10.1186/s12917-024-04067-y
AXIN1
Qiangqiang He, Meiyu Qu, Chengyun Xu +10 more · 2024 · Cancer letters · Elsevier · added 2026-04-24
Lung adenocarcinoma (LUAD), a type of non-small cell lung cancer (NSCLC), originates from not only bronchial epithelial cells but also alveolar type 2 (AT2) cells, which could differentiate into AT2-l Show more
Lung adenocarcinoma (LUAD), a type of non-small cell lung cancer (NSCLC), originates from not only bronchial epithelial cells but also alveolar type 2 (AT2) cells, which could differentiate into AT2-like cells. AT2-like cells function as cancer stem cells (CSCs) of LUAD tumorigenesis to give rise to adenocarcinoma. However, the mechanism underlying AT2 cell differentiation into AT2-like cells in LUAD remains unknown. We analyze genes differentially expressed and genes with significantly different survival curves in LUAD, and the combination of these two analyses yields 147 differential genes, in which 14 differentially expressed genes were enriched in cell cycle pathway. We next analyze the protein levels of these genes in LUAD and find that Cyclin-A2 (CCNA2) is closely associated with LUAD tumorigenesis. Unexpectedly, high CCNA2 expression in LUAD is restrictedly associated with smoking and independent of other driver mutations. Single-cell sequencing analyses reveal that CCNA2 is predominantly involved in AT2-like cell differentiation, while inhibition of CCNA2 significantly reverses smoking-induced AT2-like cell differentiation. Mechanistically, CCNA2 binding to CDK2 phosphorylates the AXIN1 complex, which in turn induces ubiquitination-dependent degradation of β-catenin and inhibits the WNT signaling pathway, thereby failing AT2 cell maintenance. These results uncover smoking-induced CCNA2 overexpression and subsequent WNT/β-catenin signaling inactivation as a hitherto uncharacterized mechanism controlling AT2 cell differentiation and LUAD tumorigenesis. Show less
no PDF DOI: 10.1016/j.canlet.2024.216922
AXIN1
Zhenfeng Chen, Bingqi Lin, Xiaodan Yao +11 more · 2024 · Cell communication and signaling : CCS · BioMed Central · added 2026-04-24
Diabetic angiogenesis is closely associated with disabilities and death caused by diabetic microvascular complications. Advanced glycation end products (AGEs) are abnormally accumulated in diabetic pa Show more
Diabetic angiogenesis is closely associated with disabilities and death caused by diabetic microvascular complications. Advanced glycation end products (AGEs) are abnormally accumulated in diabetic patients and are a key pathogenic factor for diabetic angiogenesis. The present study focuses on understanding the mechanisms underlying diabetic angiogenesis and identifying therapeutic targets based on these mechanisms. In this study, AGE-induced angiogenesis serves as a model to investigate the mechanisms underlying diabetic angiogensis. Mouse aortic rings, matrigel plugs, and HUVECs or 293T cells were employed as research objects to explore this pathological process by using transcriptomics, gene promoter reporter assays, virtual screening and so on. Here, we found that AGEs activated Wnt/β-catenin signaling pathway and enhanced the β-catenin protein level by affecting the expression of β-catenin degradation-related genes, such as FZDs (Frizzled receptors), LRPs (LDL Receptor Related Proteins), and AXIN1. AGEs could also mediate β-catenin Y142 phosphorylation through VEGFR1 isoform5. These dual effects of AGEs elevated the nuclear translocation of β-catenin and sequentially induced the expression of KDR (Kinase Insert Domain Receptor) and HDAC9 (Histone Deacetylase 9) by POU5F1 and NANOG, respectively, thus mediating angiogenesis. Finally, through virtual screening, Bioymifi, an inhibitor that blocks VEGFR1 isoform5-β-catenin complex interaction and alleviates AGE-induced angiogenesis, was identified. Collectively, this study offers insight into the pathophysiological functions of β-catenin in diabetic angiogenesis. Show less
📄 PDF DOI: 10.1186/s12964-024-01566-1
AXIN1
Peiyi Xie, Mincheng Yu, Bo Zhang +19 more · 2024 · Journal of hepatology · Elsevier · added 2026-04-24
The effectiveness of immune checkpoint inhibitor (ICI) therapy for hepatocellular carcinoma (HCC) is limited by treatment resistance. However, the mechanisms underlying immunotherapy resistance remain Show more
The effectiveness of immune checkpoint inhibitor (ICI) therapy for hepatocellular carcinoma (HCC) is limited by treatment resistance. However, the mechanisms underlying immunotherapy resistance remain elusive. We aimed to identify the role of CT10 regulator of kinase-like (CRKL) in resistance to anti-PD-1 therapy in HCC. Gene expression in HCC specimens from 10 patients receiving anti-PD-1 therapy was identified by RNA-sequencing. A total of 404 HCC samples from tissue microarrays were analyzed by immunohistochemistry. Transgenic mice (Alb-Cre/Trp53 CRKL was identified as a candidate anti-PD-1-resistance gene using a pooled genetic screen. CRKL overexpression nullifies anti-PD-1 treatment efficacy by mobilizing tumor-associated neutrophils (TANs), which block the infiltration and function of CD8 Activation of the CRKL/β-catenin/VEGFα and CXCL1 axis is a critical obstacle to successful anti-PD-1 therapy. Therefore, CRKL inhibitors combined with anti-PD-1 could be useful for the treatment of HCC. Here, we found that CRKL was overexpressed in anti-PD-1-resistant hepatocellular carcinoma (HCC) and that CRKL upregulation promotes anti-PD-1 resistance in HCC. We identified that upregulation of the CRKL/β-catenin/VEGFα and CXCL1 axis contributes to anti-PD-1 tolerance by promoting infiltration of tumor-associated neutrophils. These findings support the strategy of bevacizumab-based immune checkpoint inhibitor combination therapy, and CRKL inhibitors combined with anti-PD-1 therapy may be developed for the treatment of HCC. Show less
no PDF DOI: 10.1016/j.jhep.2024.02.009
AXIN1
Wenbin Shi, Yuli Xu, Anan Zhang +3 more · 2024 · Advances in rheumatology (London, England) · BioMed Central · added 2026-04-24
This study aimed to investigate the causal impact of inflammatory cytokines on Sjogren's Syndrome (SS) and to identify potential biomarkers for SS clinical management using Mendelian Randomization (MR Show more
This study aimed to investigate the causal impact of inflammatory cytokines on Sjogren's Syndrome (SS) and to identify potential biomarkers for SS clinical management using Mendelian Randomization (MR). Leveraging GWAS summary data of inflammatory cytokines and SS, we executed the first two-sample MR analysis. Genetic variants from prior GWASs associated with circulating inflammatory cytokines served as instrumental variables (IVs). Data regarding cytokines were analyzed using the Olink Target-96 Inflammation panel, synthesizing data from 14,824 participants. GWAS summary statistics for SS were procured from the UK Biobank, focusing on samples of European ancestry. To discern the causal relationship between inflammatory cytokines and SS, several MR methodologies, including inverse variance weighted (IVW) and MR-Egger regression, were applied. After rigorous IV quality control, 91 cytokines were incorporated into the MR analysis. The IVW analysis identified 8 cytokines with a positive association to SS: Axin-1 (OR 2.56, 95% CI 1.07-6.10), T-cell surface glycoprotein CD5 (OR 1.81, 95% CI 1.08-3.02), CUDP1 (OR 1.61, 95% CI 1.00-2.58), CXCL10 (OR 1.92, 95% CI 1.25-2.95), IL-4 (OR 2.18, 95% CI 1.22-3.91), IL-7 (OR 2.35, 95% CI 1.27-4.33), MCP-2 (OR 1.27, 95% CI 1.05-1.54), and TNFRSF9 (OR 1.83, 95% CI 1.03-3.24), suggesting their potential in increasing SS risk. Our study conducted through MR, identified various inflammatory cytokines associated with SS risk, validating some previous research results and offering some new potential biomarkers for SS. However, these findings necessitate further research for validation and exploration of their precise role in the onset and progression of SS. Show less
📄 PDF DOI: 10.1186/s42358-024-00354-2
AXIN1
Ya Su, Qiong Wang, Feng Gao +8 more · 2024 · Journal of the American Heart Association · added 2026-04-24
We enrolled 163 participants with CSVD (114 cerebral amyloid angiopathy and 49 hypertensive hemorrhage), and 96 cognitively unimpaired elders and 40 participants with Alzheimer's disease as controls. Show more
We enrolled 163 participants with CSVD (114 cerebral amyloid angiopathy and 49 hypertensive hemorrhage), and 96 cognitively unimpaired elders and 40 participants with Alzheimer's disease as controls. We measured BACE1 activity using a synthetic fluorescence substrate enzyme-linked immunosorbent assay. We used regression models to investigate associations between BACE1 and imaging and blood markers as well as clinical outcomes in CSVD. Plasma BACE1 activity was significantly higher in CSVD (median 862.0 relative fluorescence units [RFU], interquartile range 700.6-1032.9) compared with elder controls (522.5 RFU, 438.3-662.1, Plasma BACE1 activity is moderately increased and associated with neurodegeneration and cognitive impairment risk in CSVD. It indicates that BACE1 is a promising biomarker especially for CSVD-related neurodegeneration. Show less
📄 PDF DOI: 10.1161/JAHA.124.036204
BACE1
J Du, G Xu, W Zhang +3 more · 2024 · SAR and QSAR in environmental research · Taylor & Francis · added 2026-04-24
J Du, G Xu, W Zhang, J Cong, X Si, B Wei Show less
BACE1 has been regarded as an essential drug design target for treating Alzheimer's disease (AD). Multiple independent Gaussian accelerated molecular dynamics simulations (GaMD), deep learning (DL), a Show more
BACE1 has been regarded as an essential drug design target for treating Alzheimer's disease (AD). Multiple independent Gaussian accelerated molecular dynamics simulations (GaMD), deep learning (DL), and molecular mechanics general Born surface area (MM-GBSA) method are integrated to elucidate the molecular mechanism underlying the effect of D93 and D289 protonation on binding of inhibitors OV6 and 4B2 to BACE1. The GaMD trajectory-based DL successfully identifies significant function domains. Dynamic analysis shows that the protonation of D93 and D289 strongly affects the structural flexibility and dynamic behaviour of BACE1. Free energy landscapes indicate that inhibitor-bound BACE1s have more conformational states in the protonated states than the wild-type (WT) BACE1, and show more binding poses of inhibitors. Binding affinities calculated using the MM-GBSA method indicate that the protonation of D93 and D289 highly disturbs the binding ability of inhibitors to BACE1. In addition, the protonation of two residues significantly affects the hydrogen bonding interactions (HBIs) of OV6 and 4B2 with BACE1, altering their binding activity to BACE1. The binding hot spots of BACE1 recognized by residue-based free energy estimations provide rational targeting sites for drug design towards BACE1. This study is anticipated to provide theoretical aids for drug development towards treatment of AD. Show less
no PDF DOI: 10.1080/1062936X.2024.2419911
BACE1
Hao Chen, Guimin Hou, Tian Lan +5 more · 2024 · Heliyon · Elsevier · added 2026-04-24
Hepatocellular carcinoma (HCC) is among the most prevalent digestive system malignancies and is associated with a poor prognosis. Necroptosis, a form of regulated death mediated by death receptors, ex Show more
Hepatocellular carcinoma (HCC) is among the most prevalent digestive system malignancies and is associated with a poor prognosis. Necroptosis, a form of regulated death mediated by death receptors, exhibits characteristics of both necrosis and apoptosis. Long non-coding RNAs (lncRNAs) have been identified as crucial regulators in tumor necroptosis. This study aims to identify the necroptosis-related lncRNAs (np-lncRNA) in HCC and investigate their relationships with prognosis. The RNA-sequencing data, along with clinicopathological and survival information of HCC patients were sourced from The Cancer Genome Atlas (TCGA) database. The np-lncRNAs were analyzed to assess their potential in predicting HCC prognosis. Prognostic signatures related to necroptosis were constructed using stepwise multivariate Cox regression analysis. The prognosis of patients was compared using Kaplan-Meier (KM) analysis. The accuracy of the prognostic signature was evaluated using Receiver operating characteristic (ROC) analysis and decision curve analysis (DCA). Quantitative real-time polymerase chain reaction(qPCR) was employed to validate the lncRNAs expression levels of lncRNAs among samples from an independent cohort. The np-lncRNAs ZFPM2-AS1, AC099850.3, BACE1-AS, KDM4A-AS1 and MKLN1-AS were identified as potential prognostic biomarkers. The prognostic signature constructed from these np-lncRNAs achieved an Area Under the Curve (AUC) of 0.773. Based on the risk score derived from the signature, patients were divided into two groups, with the high-risk group exhibiting poorer overall survival. Gene Set Enrichment Analysis (GSEA) revealed significantly different between the low risk and high risk groups in tumor-related pathways (such as mTOR, MAPK and p53 signaling pathways) and immune-related functions (like T cell receptor signaling pathway and natural killer cell mediated cytotoxicity). The increased expression of np-lncRNAs was confirmed in another independent HCC cohort. This signature offers a dependable method for forecasting the prognosis of HCC patients. Our findings indicate a subset of np-lncRNA biomarkers that could be utilized for prognosis prediction and personalized treatment strategies of HCC patients. Show less
📄 PDF DOI: 10.1016/j.heliyon.2024.e37403
BACE1
Xingyi Zhao, Qiaoguan Hu, Xiaoqian Wang +11 more · 2024 · European journal of medicinal chemistry · Elsevier · added 2026-04-24
Alzheimer's disease (AD) is the most common form of dementia among the elderly, accounting for 60 %-70 % of cases. At present, the pathogenesis of this condition remains unclear, but the hydrolysis of Show more
Alzheimer's disease (AD) is the most common form of dementia among the elderly, accounting for 60 %-70 % of cases. At present, the pathogenesis of this condition remains unclear, but the hydrolysis of acetylcholine (ACh) is thought to play a role. Acetylcholinesterase (AChE) can break down ACh transmission from the presynaptic membrane and stop neurotransmitters' excitatory effect on the postsynaptic membrane, which plays a key role in nerve conduction. Acetylcholinesterase inhibitors (AChEIs) can delay the hydrolysis of acetylcholine (ACh), which represents a key strategy for treating AD. Due to its complex etiology, AD has proven challenging to treat. Various inhibitors and antagonists targeting key enzymes and proteins implicated in the disease's pathogenesis have been explored as potential therapeutic agents. These include Glycogen Synthase Kinase 3β (GSK-3β) inhibitors, β-site APP Cleaving Enzyme (BACE-1) inhibitors, Monoamine Oxidase (MAO) inhibitors, Phosphodiesterase inhibitors (PDEs), N-methyl--aspartic Acid (NMDA) antagonists, Histamine 3 receptor antagonists (H3R), Serotonin receptor subtype 4 (5-HT4R) antagonists, Sigma1 receptor antagonists (S1R) and soluble Epoxide Hydrolase (sEH) inhibitors. The drug development strategy of multi-target-directed ligands (MTDLs) offers unique advantages in the treatment of complex diseases. On the one hand, it can synergistically enhance the therapeutic efficacy of single-target drugs. On the other hand, it can also reduce the side effects. In this review, we discuss the design strategy of dual inhibitors based on acetylcholinesterase and the structure-activity relationship of these drugs. Show less
no PDF DOI: 10.1016/j.ejmech.2024.116810
BACE1
Xinhua Zhou, Zeyu Zhu, Shaoming Kuang +8 more · 2024 · Pharmaceuticals (Basel, Switzerland) · MDPI · added 2026-04-24
Alzheimer's disease (AD) is a neurodegenerative disorder associated with age. A wealth of evidence indicates that the amyloid β (Aβ) aggregates result from dyshomeostasis between Aβ production and cle Show more
Alzheimer's disease (AD) is a neurodegenerative disorder associated with age. A wealth of evidence indicates that the amyloid β (Aβ) aggregates result from dyshomeostasis between Aβ production and clearance, which plays a pivotal role in the pathogenesis of AD. Consequently, therapies targeting Aβ reduction represent a promising strategy for AD intervention. Tetramethylpyrazine nitrone (TBN) is a novel tetramethylpyrazine derivative with potential for the treatment of AD. Previously, we demonstrated that TBN markedly enhanced cognitive functions and decreased the levels of Aβ, APP, BACE 1, and hyperphosphorylated tau in 3×Tg-AD mice. However, the mechanism by which TBN inhibits Aβ deposition is still unclear. In this study, we employed APP/PS1 mice treated with TBN (60 mg/kg, ig, bid) for six months, and N2a/APP695swe cells treated with TBN (300 μM) to explore the mechanism of TBN in Aβ reduction. Our results indicate that TBN significantly alleviated cognitive impairment and reduced Aβ deposition in APP/PS1 mice. Further investigation of the underlying mechanisms revealed that TBN decreased the expression of APP and BACE1, activated the AMPK/mTOR/ULK1 autophagy pathway, inhibited the PI3K/AKT/mTOR/ULK1 autophagy pathway, and decreased the phosphorylation levels of JNK and ERK in APP/PS1 mice. Moreover, TBN was found to significantly reduce the mRNA levels of APP and BACE1, as well as those of SP1, CTCF, TGF-β, and NF-κB, transcription factors involved in regulating gene expression. Additionally, TBN was observed to decrease the level of Show less
📄 PDF DOI: 10.3390/ph17081005
BACE1
Yuanyuan Zong, Hailin Wang, Wei Dong +6 more · 2024 · Brain research · Elsevier · added 2026-04-24
no PDF DOI: 10.1016/j.brainres.2024.149126
BACE1
Chunli Zou, Tingting Yang, Xinfeng Huang +4 more · 2024 · Heliyon · Elsevier · added 2026-04-24
Alzheimer's disease is the most common form of dementia and is characterized by cognitive impairment. The disruption of autophagosome-lysosome function has been linked to the pathogenesis of Alzheimer Show more
Alzheimer's disease is the most common form of dementia and is characterized by cognitive impairment. The disruption of autophagosome-lysosome function has been linked to the pathogenesis of Alzheimer's disease. Tris (1,3-dichloro-2-propyl) phosphate (TDCIPP) is a widely used organophosphorus flame retardant that has the potential to cause neuronal damage. We found that TDCIPP significantly increased the expression of β-site amyloid precursor protein (APP)-cleaving enzyme 1 (BACE1), presenilin-1 (PS1) and Aβ42. Proteomic studies with TMT labeling revealed changes in the profiles of N2a-APPswe cells after exposure to TDCIPP. Proteomic and bioinformatics analyses revealed that lysosomal proteins were dysregulated in N2a-APPswe cells after treatment with TDCIPP. The LC3, P62, CTSD, and LAMP1 levels were increased after TDCIPP exposure, and dysregulated protein expression was validated by Western blotting. The exposure to TDCIPP led to the accumulation of autophagosomes, and this phenomenon was enhanced in the presence of chloroquine (CQ). Our results revealed for the first time that TDCIPP could be a potential environmental risk factor for AD development. The inhibition of autophagosome-lysosome fusion may have a significant impact on the generation of Aβ1-42 in response to TDCIPP. Show less
📄 PDF DOI: 10.1016/j.heliyon.2024.e26832
BACE1
Heng-Cai Wang, Wei Yang, Ling Xu +6 more · 2024 · Advanced healthcare materials · Wiley · added 2026-04-24
Microglia-mediated inflammation is involved in the pathogenesis of Alzheimer's disease (AD), whereas human fibroblast growth factor 21 (hFGF21) has demonstrated the ability to regulate microglia activ Show more
Microglia-mediated inflammation is involved in the pathogenesis of Alzheimer's disease (AD), whereas human fibroblast growth factor 21 (hFGF21) has demonstrated the ability to regulate microglia activation in Parkinson's disease, indicating a potential therapeutic role in AD. However, challenges such as aggregation, rapid inactivation, and the blood-brain barrier hinder its effectiveness in treating AD. This study develops targeted delivery of hFGF21 to activated microglia using BV2 cell membrane-coated PEGylated liposomes (hFGF21@BCM-LIP), preserving the bioactivity of hFGF21. In vitro, hFGF21@BCM-LIP specifically targets Aβ Show less
no PDF DOI: 10.1002/adhm.202400125
BACE1
Tianshu Shi, Siyu Shen, Yong Shi +21 more · 2024 · Nature metabolism · Nature · added 2026-04-24
Ageing increases susceptibility to neurodegenerative disorders, such as Alzheimer's disease (AD). Serum levels of sclerostin, an osteocyte-derived Wnt-β-catenin signalling antagonist, increase with ag Show more
Ageing increases susceptibility to neurodegenerative disorders, such as Alzheimer's disease (AD). Serum levels of sclerostin, an osteocyte-derived Wnt-β-catenin signalling antagonist, increase with age and inhibit osteoblastogenesis. As Wnt-β-catenin signalling acts as a protective mechanism for memory, we hypothesize that osteocyte-derived sclerostin can impact cognitive function under pathological conditions. Here we show that osteocyte-derived sclerostin can cross the blood-brain barrier of old mice, where it can dysregulate Wnt-β-catenin signalling. Gain-of-function and loss-of-function experiments show that abnormally elevated osteocyte-derived sclerostin impairs synaptic plasticity and memory in old mice of both sexes. Mechanistically, sclerostin increases amyloid β (Aβ) production through β-catenin-β-secretase 1 (BACE1) signalling, indicating a functional role for sclerostin in AD. Accordingly, high sclerostin levels in patients with AD of both sexes are associated with severe cognitive impairment, which is in line with the acceleration of Αβ production in an AD mouse model with bone-specific overexpression of sclerostin. Thus, we demonstrate osteocyte-derived sclerostin-mediated bone-brain crosstalk, which could serve as a target for developing therapeutic interventions against AD. Show less
📄 PDF DOI: 10.1038/s42255-024-00989-x
BACE1
Yuxuan Ma, Wuxiang Sun, Jing Bai +11 more · 2024 · CNS neuroscience & therapeutics · Blackwell Publishing · added 2026-04-24
Alzheimer's disease (AD) is a significant global health concern, and it is crucial that we find effective methods to prevent or slow down AD progression. Recent studies have highlighted the essential Show more
Alzheimer's disease (AD) is a significant global health concern, and it is crucial that we find effective methods to prevent or slow down AD progression. Recent studies have highlighted the essential role of blood vessels in clearing Aβ, a protein that contributes to AD. Scientists are exploring blood biomarkers as a potential tool for future AD diagnosis. One promising method that may help prevent AD is remote ischemic conditioning (RIC). RIC involves using sub-lethal ischemic-reperfusion cycles on limbs. However, a comprehensive understanding of how RIC can prevent AD and its long-term effectiveness is still lacking. Further research is essential to fully comprehend the potential benefits of RIC in preventing AD. Female wild-type (WT) and APP/PS1 transgenic rats, aged 12 months, underwent ovariectomy and were subsequently assigned to WT, APP/PS1, and APP/PS1 + RIC groups. RIC was conducted five times a week for 4 weeks. The rats' depressive and cognitive behaviors were evaluated using force swimming, open-field tests, novel objective recognition, elevated plus maze, and Barnes maze tests. Evaluation of the neurovascular unit (NVU), synapses, vasculature, astrocytes, and microglia was conducted using immunofluorescence staining (IF), Western blot (WB), and transmission electron microscopy (TEM). Additionally, the cerebro-vasculature was examined using micro-CT, and cerebral blood flow (CBF) was measured using Speckle Doppler. Blood-brain barrier (BBB) permeability was determined by measuring the Evans blue leakage. Finally, Aβ levels in the rat frontal cortex were measured using WB, ELISA, or IF staining. RIC enhanced memory-related protein expression and rescued depressive-like behavior and cognitive decline in APP/PS1 transgenic rats. Additionally, the intervention protected NVU in the rat frontal cortex, as evidenced by (1) increased expression of TJ (tight junction) proteins, pericyte marker PDGFRβ, and glucose transporter 1 (GLUT1), as well as decreased VCAM1; (2) mitigation of ultrastructure impairment in neuron, cerebral vascular, and astrocyte; (3) upregulation of A2 astrocyte phenotype markers and downregulation of A1 phenotype markers, indicating a shift toward a healthier phenotype. Correspondingly, RIC intervention alleviated neuroinflammation, as evidenced by the decreased Iba1 level, a microglia marker. Meanwhile, RIC intervention elevated CBF in frontal cortex of the rats. Notably, RIC intervention effectively suppressed Aβ toxicity, as demonstrated by the enhancement of α-secretase and attenuation of β-secretase (BACE1) and γ- secretase and Aβ1-42 and Aβ1-40 levels as well. Chronic RIC intervention exerts vascular and neuroprotective roles, suggesting that RIC could be a promising therapeutic strategy targeting the BBB and NVU during AD development. Show less
📄 PDF DOI: 10.1111/cns.14613
BACE1
Zhifang Wang, Jingpei Zhou, Bin Zhang +4 more · 2024 · Behavioural brain research · Elsevier · added 2026-04-24
The primary aim of this study was to examine the correlation between the formation of Aβ plaques and autophagy, which is regulated by β-asarone and the lncRNA BACE1-AS. Additionally, the study sought Show more
The primary aim of this study was to examine the correlation between the formation of Aβ plaques and autophagy, which is regulated by β-asarone and the lncRNA BACE1-AS. Additionally, the study sought to explore potential targets of the drug in inhibiting the deposition of toxic AD-related proteins and restoring impaired mitochondrial and autophagic functions. SHY5Y cells were utilized to construct a stable Alzheimer's disease (AD) model, followed by the utilization of interference and overexpression lentiviruses targeting BACE1-AS to establish a cell model. The cells were categorized into five groups, including a normal group, siRNA/BACE1 group, and β-asarone group. The fluorescence quantitative PCR technique was employed to assess the disparity in BACE1 mRNA expression, while changes in immunofluorescence (IF) were observed to determine the stable interference titre and action time of the lentiviruses. Additionally, western blotting (WB) and fluorescence quantitative PCR were employed to evaluate the expression of proteins and mRNAs associated with AD and autophagy. The findings demonstrated a significant elevation in BACE1 expression levels in brain tissue among individuals with AD compared to those without the condition. Moreover, the results indicated that the introduction of β-asarone led to an increase in the expression of the BACE1-AS gene in the cell group transfected with plasmid H12732. Furthermore, it was observed that β-asarone enhanced the expression levels of shRNA and BACE1 after 72 h. In contrast, β-asarone suppressed the expression of PS1, Aβ, BACE1, APP, and p62, while promoting the expression of syn, LC3 I/II, and Beclin-1. Based on these findings, it can be concluded that β-Asarone exerts a comprehensive influence on the expression of proteins associated with AD and synaptic function. β-Asarone exhibits the potential to mitigate Aβ deposition by impeding the expression of lncBACE1, thereby facilitating autophagy through the suppression of BACE1's inhibitory impact on autophagy. This complements the self-enhancing effect of autophagy. Show less
no PDF DOI: 10.1016/j.bbr.2024.114896
BACE1
Xiuhua Wei, Jie Fan, Yuanqiang Hao +4 more · 2024 · Talanta · Elsevier · added 2026-04-24
A novel electrochemiluminescence (ECL) and electrochemical dual-mode sensor was developed for detecting the activity of beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) and screening its Show more
A novel electrochemiluminescence (ECL) and electrochemical dual-mode sensor was developed for detecting the activity of beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) and screening its inhibitor. Specifically, the adamantane (ADA)-functionalized peptide (P1), a designed substrate peptide for BACE1, was immobilized on the electrode surface via host-guest interaction between β-cyclodextrin (β-CD) and ADA. The aggregation of the peptide (P2) and luminol co-functionalized silver nanoparticles could be induced by cucurbit [8]uril (CB[8] due to the ability of CB[8] to accommodate two aromatic residues simultaneously. The obtained (CB[8]-P2-AgNPs-luminol) Show less
no PDF DOI: 10.1016/j.talanta.2023.124904
BACE1
Jie Fan, Xiuhua Wei, Hui Dong +4 more · 2024 · Critical reviews in analytical chemistry · Taylor & Francis · added 2026-04-24
Alzheimer's disease (AD) is a degenerative disease of the central nervous system. The pathogenesis is still not fully clear. One of the main histopathological manifestations is senile plaques formed b Show more
Alzheimer's disease (AD) is a degenerative disease of the central nervous system. The pathogenesis is still not fully clear. One of the main histopathological manifestations is senile plaques formed by β-amyloid (Aβ) accumulation. Aβ is generated from the sequential proteolysis of amyloid precursor protein (APP) by β-secretase [i.e. β-site APP cleaving enzyme 1 (BACE1)] and γ-secretase, with a rate-limiting step controlled by BACE1 activity. Therefore, inhibiting BACE1 activity has become a potential therapeutic strategy for AD. The development of reliable detection methods for BACE1 activity plays an important role in early diagnosis of AD and evaluation of the therapeutic effect of new drugs for AD. This article has reviewed the recent advances in BACE1 activity detection techniques. The challenges of applying these analysis techniques to early clinical diagnosis of AD and development trends of the detection techniques have been prospected. Show less
no PDF DOI: 10.1080/10408347.2022.2132812
BACE1

A

Yalu Cui, Wenping Xu, Jinpei Liu +6 more · 2024 · Genes & diseases · Elsevier · added 2026-04-24
📄 PDF DOI: 10.1016/j.gendis.2023.02.042
BBS4
Liming Yu, Tao Huang, Jikai Zhao +10 more · 2024 · Free radical biology & medicine · Elsevier · added 2026-04-24
Metabolic reprogramming of vascular smooth muscle cell (VSMC) plays a critical role in the pathogenesis of thoracic aortic dissection (TAD). Previous researches have mainly focused on dysregulation of Show more
Metabolic reprogramming of vascular smooth muscle cell (VSMC) plays a critical role in the pathogenesis of thoracic aortic dissection (TAD). Previous researches have mainly focused on dysregulation of fatty acid or glucose metabolism, while the impact of amino acids catabolic disorder in VSMCs during the development of TAD remains elusive. Here, we identified branched-chain amino acid (BCAA) catabolic defect as a metabolic hallmark of TAD. The bioinformatics analysis and data from human aorta revealed impaired BCAA catabolism in TAD individuals. This was accompanied by upregulated branched-chain α-ketoacid dehydrogenase kinase (BCKDK) expression and BCKD E1 subunit alpha (BCKDHA) phosphorylation, enhanced vascular inflammation, and hyperactivation of mTOR signaling. Further in vivo experiments demonstrated that inhibition of BCKDK with BT2 (a BCKDK allosteric inhibitor) treatment dephosphorylated BCKDHA and re-activated BCAA catabolism, attenuated VSMCs phenotypic switching, alleviated aortic remodeling, mitochondrial reactive oxygen species (ROS) damage and vascular inflammation. Additionally, the beneficial actions of BT2 were validated in a TNF-α challenged murine VSMC cell line. Meanwhile, rapamycin conferred similar beneficial effects against VSMC phenotypic switching, cellular ROS damage as well as inflammatory response. However, co-treatment with MHY1485 (a classic mTOR activator) reversed the beneficial effects of BT2 by reactivating mTOR signaling. Taken together, the in vivo and in vitro evidence showed that impairment of BCAA catabolism resulted in aortic accumulation of BCAA and further caused VSMC phenotypic switching, mitochondrial ROS damage and inflammatory response via mTOR hyperactivation. BCKDK and mTOR signaling may serve as the potential drug targets for the prevention and treatment of TAD. Show less
no PDF DOI: 10.1016/j.freeradbiomed.2023.11.002
BCKDK
Zulfiqar Ahmed, Weixuan Xiang, Fuwen Wang +4 more · 2024 · Animal genetics · Blackwell Publishing · added 2026-04-24
Kashmir cattle, which were kept by local pastoralists for centuries, are exceptionally resilient and adaptive to harsh environments. Despite its significance, the genomic characteristics of this cattl Show more
Kashmir cattle, which were kept by local pastoralists for centuries, are exceptionally resilient and adaptive to harsh environments. Despite its significance, the genomic characteristics of this cattle breed remain elusive. This study utilized whole genome sequences of Kashmir cattle (n = 20; newly sequenced) alongside published whole genomes of 32 distinct breeds and seven core cattle populations (n = 135). The analysis identified ~25.87 million biallelic single nucleotide polymorphisms in Kashmir cattle, predominantly in intergenic and intron regions. Population structure analyses revealed distinct clustering patterns of Kashmir cattle with proximity to the South Asian, African and Chinese indicine cattle populations. Genetic diversity analysis of Kashmir cattle demonstrated lower inbreeding and greater nucleotide diversity than analyzed global breeds. Homozygosity runs indicated less consanguineous mating in Kashmir cattle compared with European taurine breeds. Furthermore, six selection sweep detection methods were used within Kashmir cattle and other cattle populations to identify genes associated with vital traits, including immunity (BOLA-DQA5, BOLA-DQB, TNFAIP8L, FCRL4, AOAH, HIF1AN, FBXL3, MPEG1, CDC40, etc.), reproduction (GOLGA4, BRWD1, OSBP2, LEO1 ADCY5, etc.), growth (ADPRHL1, NRG2, TCF12, TMOD4, GBP4, IGF2, RSPO3, SCD, etc.), milk composition (MRPS30 and CSF1) and high-altitude adaptation (EDNRA, ITPR2, AGBL4 and SCG3). These findings provide essential genetic insights into the characteristics and establish the foundation for the scientific conservation and utilization of Kashmir cattle breed. Show less
no PDF DOI: 10.1111/age.13434
BRWD1
Jie Gao, Mai Re YanMu Rouzi, Huihui Zhang +4 more · 2024 · Acta diabetologica · Springer · added 2026-04-24
We investigated the correlation between serum C1q/TNF-related protein 4 (CTRP4) level and flow-mediated dilation (FMD) in patients with type 2 diabetes mellitus (T2DM), and evaluated the biological ef Show more
We investigated the correlation between serum C1q/TNF-related protein 4 (CTRP4) level and flow-mediated dilation (FMD) in patients with type 2 diabetes mellitus (T2DM), and evaluated the biological effects of CTRP4 on human umbilical vein endothelial cells (HUVECs). A group of 165 patients diagnosed with T2DM were included in this study. Endothelial function was measured with the examination of brachial artery FMD. ELISA kit was used to measure the levels of CTRP4 in serum. HUVECs were stimulated with recombinant CTRP4 protein to assess its biological functions. The levels of CTRP4 showed a significant variation among three groups based on FMD tertiles (p = 0.001). What's more, FMD had a significant difference among three CTRP4 tertile groups (p < 0.05) and was negatively related to serum CTRP4 levels (r = -0.270, p < 0.001). In T2DM patients, logistic regression analysis demonstrated that CTRP4 was the primary influence factor of low FMD (p < 0.01). In receiver operating characteristic curve analysis, the area under the curve of CTRP4 for predicting low FMD was 0.66 (95%CI 0.58-0.75). When stimulated HUVECs with recombinant CTRP4 protein, we found that CTRP4 could concentration-dependently ameliorate proliferation and migration of HUVECs in wounding healing and transwell assay. This protein could also decrease the expression of IL-6 and TNF-α and promote the release of NO in HUVEC supernatants, with suppression of NF-κB and STAT3 phosphorylation. Serum CTRP4 concentrations were negatively associated with FMD. CTRP4 alleviated proliferation, migration and inflammation in HUVECs through the suppression of NF-κB and STAT3 signaling pathways. Show less
📄 PDF DOI: 10.1007/s00592-023-02228-3
C1QTNF4
Xiaoting Xu, Cong Lai, Jiawen Luo +9 more · 2024 · Cellular oncology (Dordrecht, Netherlands) · Springer · added 2026-04-24
The Chromobox (CBX) family proteins are crucial elements of the epigenetic regulatory machinery and play a significant role in the development and advancement of cancer. Nevertheless, there is limited Show more
The Chromobox (CBX) family proteins are crucial elements of the epigenetic regulatory machinery and play a significant role in the development and advancement of cancer. Nevertheless, there is limited understanding regarding the role of CBXs in development or progression of prostate cancer (PCa). Our objective is to develop a unique prognostic model associated with CBXs to improve the accuracy of predicting outcomes of patients with PCa. Data from TCGA and GEO databases were analyzed to assess differential expression, prognostic value, gene pathway enrichment, and immune cell infiltration. COX regression analysis was utilized to identify the independent prognostic factors that impact disease-free survival (DFS). The expression of CBX2 and FOXP3 CBX2, CBX3, CBX4, and CBX8 were upregulated, while CBX6 and CBX7 were downregulated in PCa tissues. CBXs expression varied by stage and grade. Elevated expression of CBX1, CBX2, CBX3, CBX4 and CBX8 is correlated with poor outcome. CBX2 expression, T stage, and Gleason score were independent prognostic factors. The expression level of CBX2 in PCa tissues was significantly higher than that in adjacent normal tissues. More Treg infiltration was observed in the group with high CBX2 expression. CBX2 expression affected PCa cell growth, migration, and invasion. CBX2 is involved in the development and advancement of PCa, suggesting its potential as a reliable prognostic indicator for PCa patients. Show less
no PDF DOI: 10.1007/s13402-024-00929-7
CBX1
Jinghuan Wang, Subei Tan, Yuyu Zhang +6 more · 2024 · Cell death and differentiation · Nature · added 2026-04-24
The aberrant expression of methyltransferase Set7/9 plays a role in various diseases. However, the contribution of Set7/9 in ischemic stroke remains unclear. Here, we show ischemic injury results in a Show more
The aberrant expression of methyltransferase Set7/9 plays a role in various diseases. However, the contribution of Set7/9 in ischemic stroke remains unclear. Here, we show ischemic injury results in a rapid elevation of Set7/9, which is accompanied by the downregulation of Sirt5, a deacetylase reported to protect against injury. Proteomic analysis identifies the decrease of chromobox homolog 1 (Cbx1) in knockdown Set7/9 neurons. Mechanistically, Set7/9 promotes the binding of Cbx1 to H3K9me2/3 and forms a transcription repressor complex at the Sirt5 promoter, ultimately repressing Sirt5 transcription. Thus, the deacetylation of Sirt5 substrate, glutaminase, which catalyzes the hydrolysis of glutamine to glutamate and ammonia, is decreased, promoting glutaminase expression and triggering excitotoxicity. Blocking Set7/9 eliminates H3K9me2/3 from the Sirt5 promoter and normalizes Sirt5 expression and Set7/9 knockout efficiently ameliorates brain ischemic injury by reducing the accumulation of ammonia and glutamate in a Sirt5-dependent manner. Collectively, the Set7/9-Sirt5 axis may be a promising epigenetic therapeutic target. Show less
no PDF DOI: 10.1038/s41418-024-01264-y
CBX1
Lulu Sun, Qilu Zhang, Mengyao Shi +9 more · 2024 · Journal of the American Heart Association · added 2026-04-24
The association of lipid-lowering drug targets and their gene variants with cardiovascular diseases has been previously clarified. However, the relationship between gene variants of lipid-lowering dru Show more
The association of lipid-lowering drug targets and their gene variants with cardiovascular diseases has been previously clarified. However, the relationship between gene variants of lipid-lowering drug targets and the adverse prognosis of ischemic stroke patients remains unclear. Multiple single-nucleotide polymorphisms associated with 6 lipid-lowering drug targets were genotyped for patients with ischemic stroke. The primary outcome was death or major disability within 2 years after ischemic stroke. Genetic risk score was constructed from significant single-nucleotide polymorphisms identified via additive models, which was calculated by multiplying the number of risk alleles at each locus by the corresponding beta coefficient and then summing the products. The rs2006760-C of the rs2006760-C of Show less
📄 PDF DOI: 10.1161/JAHA.124.036544
CETP